STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug
STAT News
MARCH 6, 2023
But they said the sum covers only the direct costs of designing and manufacturing the vaccines ― which are tailored to the unique genetic makeup of each patient’s tumor ― and that the FDA has approved the breakdown of expenses. A doctor at Duke was skeptical and would not administer the shots, Kielty said.
Let's personalize your content